---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-040767"
form_type: "8-K"
ticker: "PYXS"
cik: "0001782223"
company_name: "Pyxis Oncology, Inc."
filed_at: "2025-03-18T23:59:59+00:00"
generated_at: "2026-05-24T14:07:53.363490+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pyxis Oncology reports FY2024 net loss $77.3M; MICVO 50% ORR in HNSCC; workforce cut 20%

## Summary
- Full year 2024 net loss $77.3M ($1.32 per share) vs $73.8M ($1.85) in 2023; cash $128.4M into 2H26.
- MICVO (formerly PYX-201) achieved 50% confirmed ORR by RECIST 1.1 in R/M HNSCC Phase 1; Fast Track designation received.
- Initiated MICVO monotherapy expansion cohorts and a Phase 1/2 combo trial with Merck's KEYTRUDA; data expected 2H25/1H26.
- Workforce reduced ~20% primarily in G&A and preclinical; CMO Ken Kobayashi steps down; CEO Lara Sullivan to also serve as CMO.
- Suspended PYX-106 development; recorded $21M non-cash impairment on PYX-107 IPR&D intangible.

## SEC filing metadata
- accession: 0000950170-25-040767
- form_type: 8-K
- ticker: PYXS
- cik: 0001782223
- company_name: Pyxis Oncology, Inc.
- filed_at: 2025-03-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/0000950170-25-040767-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/pyxs-20250318.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-040767
- JSON: https://secwatch.observer/filing/0000950170-25-040767.json
- Plain text: https://secwatch.observer/filing/0000950170-25-040767.txt

## Key facts
- Executive change
  Lara S. Sullivan changed role as Chief Medical Officer at Pyxis Oncology, Inc..
  - Action: assumed
  - Role: Chief Medical Officer
  source text: Lara S. Sullivan, M.D., President and Chief Executive Officer will assume the role of Chief Medical Officer along with her current role as President and Chief Executive Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/0000950170-25-040767-index.htm
- Executive change
  Ken Kobayashi departed as Chief Medical Officer at Pyxis Oncology, Inc..
  - Action: stepping down
  - Role: Chief Medical Officer
  source text: On March 18, 2025, the Company announced that Ken Kobayashi, M.D., F.A.C.P, is stepping down from his position as the Company's Chief Medical Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782223/000095017025040767/0000950170-25-040767-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.